

Title (en)
METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST

Title (de)
VERFAHREN ZUR BEHANDLUNG VON MIT IMMUNTHERAPIE EINHERGEHENDER TOXIZITÄT UNTER VERWENDUNG EINES GM-CSF-ANTAGONISTEN

Title (fr)
MÉTHODES DE TRAITEMENT DE TOXICITÉ LIÉE À UNE IMMUNOTHÉRAPIE AU MOYEN D'UN ANTAGONISTE DU GM-CSF

Publication
EP 3849572 A4 20220713 (EN)

Application
EP 19860890 A 20190910

Priority

- US 201862729043 P 20180910
- US 201816149346 A 20181002
- US 2018053933 W 20181002
- US 201816204220 A 20181129
- US 201916248762 A 20190115
- US 201916283694 A 20190222
- US 2019050494 W 20190910

Abstract (en)
[origin: WO2020055932A2] Methods for neutralizing and/or removing human GM-CSF in a subject in need thereof, comprising administering to the subject CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) are provided. Also provided are methods for GM-CSF gene inactivation or GM-CSF knockout (KO) in a cell comprising targeted genome editing or GM-CSF gene silencing. Methods for preventing/treating immunotherapy-related toxicity, comprising administering to the subject CAR-T cells having a GM-CSF gene inactivation or GM-CSF knockout (GM-CSFk/o CAR-T cells), wherein the GM-CSF gene is inactivated or knocked out and/or a recombinant GM-CSF antagonist are provided. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having immunotherapy-related toxicity comprising administering to the subject a recombinant hGM-CSF antagonist are provided. Also provided are methods for treating or preventing immunotherapy-related toxicity in a subject, comprising administering to the subject chimeric antigen receptor-expressing T-cells (CAR-T cells), the CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells). Methods for preventing or reducing blood-brain barrier disruption in a subject treated with immunotherapy, the method comprising administering CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) to the subject, also are provided.

IPC 8 full level
C07K 16/24 (2006.01); **A61K 35/17** (2015.01); **C12N 5/0783** (2010.01)

CPC (source: EP IL KR)
A61K 31/7088 (2013.01 - KR); **A61K 35/17** (2013.01 - KR); **A61K 38/193** (2013.01 - EP IL KR); **A61K 39/001112** (2018.08 - KR); **A61K 39/4611** (2023.05 - EP IL KR); **A61K 39/4631** (2023.05 - EP IL KR); **A61K 39/464406** (2023.05 - EP IL); **A61K 39/464412** (2023.05 - EP IL KR); **A61K 39/464429** (2023.05 - EP IL); **A61K 48/005** (2013.01 - KR); **A61P 35/02** (2018.01 - EP IL KR); **C07K 16/243** (2013.01 - EP KR); **C07K 16/2866** (2013.01 - KR); **A61K 2039/505** (2013.01 - EP KR); **A61K 2039/55516** (2013.01 - EP IL KR); **A61K 2239/31** (2023.05 - EP IL KR); **A61K 2239/38** (2023.05 - EP IL KR); **A61K 2239/46** (2023.05 - KR); **A61K 2239/48** (2023.05 - EP IL); **C07K 2317/24** (2013.01 - EP KR); **C07K 2317/55** (2013.01 - EP KR); **C07K 2317/92** (2013.01 - EP)

Citation (search report)

- [X] WO 2015066262 A1 20150507 - DARTMOUTH COLLEGE [US]
- [A] WO 2009134805 A2 20091105 - KALOBIO PHARMACEUTICALS INC [US], et al
- [A] WO 2014011984 A1 20140116 - UNIV PENNSYLVANIA [US], et al
- [A] SATTVA S. NEELAPU ET AL: "Chimeric antigen receptor T-cell therapy - assessment and management of toxicities", NATURE REVIEWS CLINICAL ONCOLOGY, vol. 15, no. 1, 19 September 2017 (2017-09-19), NY, US, pages 47 - 62, XP055541211, ISSN: 1759-4774, DOI: 10.1038/nrclinonc.2017.148
- [A] D. W. LEE ET AL: "Current concepts in the diagnosis and management of cytokine release syndrome", BLOOD, vol. 124, no. 2, 29 May 2014 (2014-05-29), US, pages 188 - 195, XP055313556, ISSN: 0006-4971, DOI: 10.1182/blood-2014-05-552729
- [A] SENTMAN MARIE-LOUISE ET AL: "Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice", THE JOURNAL OF IMMUNOLOGY (1950), 15 December 2016 (2016-12-15), United States, pages 4674 - 4685, XP055823799, Retrieved from the Internet <URL:https://www.jimmunol.org/content/jimmunol/early/2016/11/12/jimmunol.1600769.full.pdf?with-ds=yes> [retrieved on 20210713], DOI: 10.4049/jimmunol.1600769
- [A] JULIANE GUST ET AL: "Endothelial Activation and Blood?Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells", CANCER DISCOVERY, vol. 7, no. 12, 26 March 2018 (2018-03-26), US, pages 1404 - 1419, XP055462614, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-17-0698

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2020055932 A2 20200319; WO 2020055932 A3 20200522; WO 2020055932 A9 20200409; WO 2020055932 A9 20200709;
AU 2019340662 A1 20210506; BR 112021004489 A2 20210720; CA 3111804 A1 20200319; CN 113164520 A 20210723;
EP 3849572 A2 20210721; EP 3849572 A4 20220713; IL 281243 A 20210429; JP 2022517461 A 20220309; KR 20210075090 A 20210622;
MX 2021002856 A 20210528; SG 11202102317P A 20210429

DOCDB simple family (application)
US 2019050494 W 20190910; AU 2019340662 A 20190910; BR 112021004489 A 20190910; CA 3111804 A 20190910;
CN 201980073595 A 20190910; EP 19860890 A 20190910; IL 28124321 A 20210303; JP 2021512883 A 20190910;
KR 20217010585 A 20190910; MX 2021002856 A 20190910; SG 11202102317P A 20190910